Mini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization
Open Access
- 15 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1448664
Abstract
Here, we provide a concise overview of recent developments in the identification of immunogenic epitopes in human apolipoprotein B-100 for immunization against atherosclerotic cardiovascular disease. Major steps forward toward a clinical application of vaccines include the design of humanized mouse models, tetramer-based identification of antigen-specific T cells, and novel analysis tools, such as single-cell RNA sequencing and cytometry by time of flight, to assess temporal and spatial changes in immune cells in atherosclerotic cardiovascular disease.Keywords
This publication has 33 references indexed in Scilit:
- What is ‘remnant cholesterol’?European Heart Journal, 2023
- Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potentialCellular and Molecular Life Sciences, 2015
- Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to HumansImmunity, 2013
- Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosisJournal of Experimental Medicine, 2010
- Diagnosis and treatment of apolipoprotein B dyslipoproteinemiasNature Reviews Endocrinology, 2010
- Natural regulatory T cells control the development of atherosclerosis in miceNature Medicine, 2006
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDLNature Medicine, 2003
- An essential role for Scurfin in CD4+CD25+ T regulatory cellsNature Immunology, 2003
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003